Does Value Mean Doing Less?
Over the past decade, the concept of improving value by avoiding excessive care has taken center stage in discussions about the U.S. health care system. As the costs of health care services has increased,...
Online Exclusives
Is It Too Soon to Celebrate the Cancer Death Rate Decline?
Earlier this year, the American Cancer Society reported the biggest one-year decline in cancer mortality ever recorded from 2016 to 2017. While fewer deaths...
Trump Administration Fetal Tissue Restrictions Disrupt Research
A recent decision by the Trump administration to limit funding for research using fetal tissue is changing scientists’ research paths and disrupting research into...
News
From the Blood Journals
Shifting From Eligibility to Optimization of Transplant in Older Adults With...
In an article published in Blood Advances, researchers from the University of Chicago reported efforts to optimize outcomes after hematopoietic cell transplantation (HCT) in...
Updates From ECHELON-1: Brentuximab Vedotin Provides Durable Efficacy in Hodgkin Lymphoma
Previously reported results from the phase III ECHELON-1 trial suggested that replacing bleomycin with brentuximab vedotin in the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)...
Multimedia
Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL
Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline...
Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...
David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML
Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...
Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis
Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...
On Location
ER-Based Protocol Improves the Accuracy of von Willebrand Disease Testing in Young Patients With Heavy Menstrual Bleeding
Watch our interview with Megan C. Brown, MD.
Researchers at Children’s Healthcare of Atlanta (CHOA) have...
Perspectives on 2019’s New Hematology Drug Approvals
In 2019, the FDA approved several new therapies – or new indications for previously approved...
Updates on ASH Clinical Practice Guidelines in Development
In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish...
Time-Limited Acalabrutinib Combination Has “Encouraging” Response Rates in Previously Untreated Chronic Lymphocytic Leukemia
Watch our interview with Benjamin Lampson, MD.
Preliminary results from a trial presented at the 2019...
Adding Navitoclax to Ruxolitinib in Ruxolitinib-Refractory Myelofibrosis Leads to Improvements in Spleen Volume, Symptom Burden
Watch our interview with Jacqueline Garcia, MD.
More than one-third of patients with myelofibrosis (MF) who...
KTE-X19: A CAR T-Cell Option for Mantle Cell Lymphoma?
According to results from the ZUMA-2 trial presented at the 2019 ASH Annual Meeting, 93%...
Latest Headlines
ASH Directions
Nancy Berliner Steps in as Editor-in-Chief of Blood, First Industry Datasets Submitted to ASH...
ASH Teams Up With Leukemia & Lymphoma Society to Connect Patients to Clinical Trials
A collaboration between the American Society of Hematology (ASH) and The...
ASH Commissions Study of U.S. Fellows, Honors Stanley Schrier with 2019 Exemplary Service Award,...
ASH Commissions 3-Year Longitudinal Study of U.S. Fellows
The American Society of Hematology (ASH), in partnership with the Fitzhugh Mullan Institute for Health Workforce Equity...
Stephen Hahn Confirmed as FDA Commissioner, Beth Shaz Becomes AABB President, and more
Stephen Hahn Confirmed as FDA Commissioner
The U.S. Senate voted 72−18 to confirm Stephen Hahn, MD, as the FDA’s new commissioner. President Donald Trump nominated...
Remembering Esmail Zanjani, Augustine Perrotta, and more
Remembering Esmail D. Zanjani (1938 – 2019)
Esmail D. Zanjani, PhD, passed away on October 5, 2019. A pioneer in fetal cell and gene therapy,...
Nobel Prize Awarded for Discovery of How Cells Sense Oxygen, ASH Members Elected to...
Nobel Prize Awarded for Discovery of How Cells Sense Oxygen
The Nobel Prize in physiology or medicine was awarded to scientists William G. Kaelin Jr.,...
Does Value Mean Doing Less?
Over the past decade, the concept of improving value by avoiding excessive care has taken center stage in discussions about the U.S. health care...
Calculating the Costs of Clinical Trials
Patients eager to contribute to research may not be fully aware of the hidden costs of trial participation
Of the three potential risks of participating...
Pediatric Hematology/Oncology: A Small Specialty Experiencing Big Changes
When Mona D. Shah, MD, MBA, finished her medical training in pediatric hematology/oncology in 2007, she estimated that most of her fellow trainees went...
